Hybrid nanoparticles for targeted cardiac regeneration via microRNA delivery

Heart failure remains one of the leading causes of morbidity and mortality worldwide, largely due to the irreversible loss of cardiomyocytes (CMs) and the formation of fibrotic scar tissue following myocardial infarction [1]. In recent years, microRNAs (miRNAs) have emerged as powerful regulators of gene expression with significant potential in cardiac regeneration. Specifically, a combination of miR-1, miR-133, miR-208, and miR-499 (known as miRcombo), has been shown to directly reprogram cardiac fibroblasts (CFs) into induced CM-like cells (iCMs). However, the clinical translation of miRNA-based therapies remains limited by the lack of safe and efficient delivery systems capable of targeting specific cell populations within the injured heart. To address this challenge, we designed novel delivery systems based on patented hybrid nanoparticles (NPs), produced via a nanoprecipitation method. These NPs consist of a lipoplex core for highly efficient miRNA encapsulation and a polymeric shell that enhances colloidal stability [2]. Surface functionalization via copper-catalyzed click chemistry enabled the conjugation of CF-targeting ligands, generating functionalized nanoparticles (F-NPs) for precise delivery. NPs and F-NPs were characterized in terms of physicochemical properties, loading efficiency, cytocompatibility, cellular uptake, and transfection performance in vitro, particularly using adult human cardiac fibroblasts (AHCFs). NPs showed a size of around 150-200 nm, negative Z-potential, excellent miRNA encapsulation efficiency, and sustained miRNA release up to 9 days in vitro. AHCFs transfected with NPs and F-NPs maintained excellent cell viability, with F-NPs showing markedly enhanced uptake compared to non-targeted NPs. Functionally, miRcombo-loaded F-NPs significantly increased the expression of cardiogenic markers, suggesting successful direct reprogramming of fibroblasts into iCMs (Figure 1). By integrating the high miRNA loading capacity of the lipid core with the enhanced stability and controlled release provided by the polymeric shell, together with cell-specific targeting conferred by the surface ligand, F-NPs effectively address key limitations of conventional delivery systems.